Review renews questions about oseltamivir benefits - CIDRAP
ABC NewsReview renews questions about oseltamivir benefitsCIDRAPJan 19, 2012 (CIDRAP News) – A lengthy new analysis of unpublished clinical trial data is renewing questions about the effectiveness of the influenza drug oseltamivir (Tamiflu), saying that although the drug shortens flu symptoms by about a day, .
NanoViricides Inc. Submits Pre-IND Briefing Document for its Anti-Influenza ... - EON: Enhanced Online News (press release)
NanoViricides Inc.
Tamiflu Data Called Inconsistent, Underreported - Medscape
MediplacementsTamiflu Data Called Inconsistent, UnderreportedMedscapeJanuary 20, 2012 — An international team of medical experts is calling into question the safety and efficacy of the anti-influenza drug oseltamivir (Tamiflu), saying that a review of unpublished data shows inconsistencies and that the drug's maker, .
Roche FY11 Profit Rises Despite Sales Drop; Sees Growth In FY12 - Update - NASDAQ
BloombergRoche FY11 Profit Rises Despite Sales Drop; Sees Growth In FY12 - UpdateNASDAQThe most commonly prescribed anti-viral medication for influenza is Oseltamivir sold under the brand name Tamiflu.
Avian flu threatens to claim additional life - Jakarta Post
Avian flu threatens to claim additional lifeJakarta PostThe ministry has also distributed anti-influenza drugs called Oseltamivir to health care facilities, including both hospitals and community health centers, free of charge.